New Drugs for Osteoporosis
This article was originally published in Start Up
Executive Summary
Significant increases in the drug-treated patient population are pushing start-ups to pursue novel mechanisms of action for treating osteoporosis.
You may also be interested in...
Therosteon BV
Rotterdam-based Therosteon is developing therapeutics for bone diseases including osteoporosis, osteoarthritis, and bone metastasis using its OsteoBLAST drug discovery platform, developed by company founder and chief scientific officer, Hans van Leeuwen.
OsteoGeneX Inc.
A discovery of the mechanism behind rare genetic condition sclerosteosis led to some new insights about bone growth. OsteoGeneX has now set out to discover small molecules that could inhibit the sclerostin pathway in a variety of potential applications including increasing bone growth in osteoporosis patients, spinal fusion and fracture repair.
Bone-Building Start-Ups
To some, the osteoporosis space may seem crowded with Big Pharma and Big Biotech drugs already on the market and more waiting in the wings. But it's a huge market with many unmet needs, offering start-ups an opportunity to develop even better, safer, more convenient drugs. In this issue we profile four emerging companies that are intent on creating novel bone-building, not just bone-preserving, drugs for the osteoporosis market.